The world’s pressing need is a vaccine to fight the current threat of Covid-19, but ultimately we may be able to develop a pan-coronavirus vaccine, Sunetra Gupta, a professor of theoretical epidemiology at the University of Oxford, UK, said at the European Commission’s annual research event.
The coronavirus pandemic disrupted the global food system and emphasised its structural inequity – from unequal food distribution to workers in the system going hungry. Experts are calling for a reimagining of the way we produce and distribute food so that everyone can access quality food. Despite producing more food by volume than humanity has to date, millions of people remain food insecure. Agriculture is also a major contributor to environmental degradation and climate change.
The pandemic left a visible imprint on car, bus and bicycle use – and at its height brought about cleaner city air – but it also disrupted another, less obvious but highly polluting sector: freight transport. Coronavirus plunged millions of planes, trucks, trains and ships into a massive experiment, disrupting supply chains as national borders closed and industries shut down. Researchers and industry are now looking to see if any of the changes will stick.
Allowing health data to flow more freely between countries in Europe could aid the fight against coronavirus while also help the region be better prepared for future pandemics, but privacy and technical considerations need to be tackled sooner rather than later, say experts.
As the coronavirus pandemic endures, the socio-economic implications of race and gender in contracting Covid-19 and dying from it have been laid bare. Artificial intelligence (AI) is playing a key role in the response, but it could also be exacerbating inequalities within our health systems – a critical concern that is dragging the technology’s limitations back into the spotlight.
The development of new medical technologies based on cutting-edge discoveries has accelerated during the coronavirus pandemic and is helping us respond to the health crisis. But for these technologies to flourish, attitudes and scepticism among investors still need to change, say researchers and start-ups.
On the southern outskirts of the city of Owensboro in Kentucky, US, there is a square, nondescript building. Inside, rows and rows of small plants are growing under artificial lights. This is a new generation biotech venture: a molecular farm. Others are springing up across the US and elsewhere – and they farm vaccines. This means that if we find a coronavirus vaccine that works, their produce could be used by households worldwide.
More than six months into the coronavirus crisis, data show that not just age, but also biological sex plays a pivotal role in the manifestation and response to Covid-19, with more men dying from acute infections versus women in the short term. This discrepancy has shined a spotlight on a key theme that has gained traction in recent years: is enough being done to account for sex and gender in disease and medicine? Not enough, says Dr Sabine Oertelt-Prigione, the chair of sex and gender-sensitive medicine at Radboud University in the Netherlands and a member of the European Commission’s expert group on gendered innovations.
Live mycelium networks, capable of information processing, could be used as building materials.
Researchers are investigating whether bilingualism enhances certain cognitive abilities.
Dr Kate Rychert studies ocean plate structures.